MARKET

INSM

INSM

Insmed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.11
-1.92
-11.98%
Closed 16:59 04/01 EDT
OPEN
15.54
PREV CLOSE
16.03
HIGH
15.87
LOW
14.07
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
34.94
52 WEEK LOW
12.09
MARKET CAP
1.27B
P/E (TTM)
-4.6395
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average INSM stock price target is 46.78 with a high estimate of 56.00 and a low estimate of 36.00.

EPS

INSM News

More
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Stifel Maintains Buy on Insmed, Lowers Price Target to $45
  • Benzinga · 03/17 14:08
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 13:48
  • Credit Suisse Maintains Outperform on Insmed, Lowers Price Target to $42
  • Benzinga · 03/17 11:58

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About INSM

Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
More

Webull offers kinds of Insmed Incorporated stock information, including NASDAQ:INSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INSM stock news, and many more online research tools to help you make informed decisions.